Stockscreener 앱 받기
0.00
100.00%
-131.87
전일 마감가:
$131.87
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$14.05B
수익:
$612.78M
순이익/손실:
$-86.37M
주가수익비율:
0.00
EPS:
-0.87
순현금흐름:
$-62.91M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$131.98
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
명칭
Intra Cellular Therapies Inc
전화
(646) 440-9333
주소
135 ROUTE 202/206, BEDMINSTER, NY
ITCI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ITCI
Intra Cellular Therapies Inc
|
0.00 | 14.05B | 612.78M | -86.37M | -62.91M | -0.87 |
|
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-24 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2025-01-31 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2024-09-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-12-11 | 개시 | TD Cowen | Outperform |
| 2023-04-20 | 개시 | Morgan Stanley | Overweight |
| 2022-08-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-06-14 | 개시 | UBS | Buy |
| 2022-04-22 | 개시 | Piper Sandler | Neutral |
| 2022-02-16 | 개시 | Goldman | Buy |
| 2021-09-23 | 개시 | Needham | Buy |
| 2020-12-15 | 개시 | BofA Securities | Buy |
| 2020-12-10 | 개시 | Goldman | Buy |
| 2020-02-20 | 개시 | Evercore ISI | Outperform |
| 2020-01-31 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-12-24 | 재확인 | Canaccord Genuity | Buy |
| 2019-08-12 | 개시 | Jefferies | Buy |
| 2018-02-26 | 개시 | JP Morgan | Overweight |
| 2018-02-08 | 개시 | RBC Capital Mkts | Outperform |
| 2017-12-15 | 개시 | Canaccord Genuity | Buy |
| 2017-11-08 | 업그레이드 | SunTrust | Hold → Buy |
| 2017-09-07 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-08-30 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2017-08-24 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-08-23 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2017-05-02 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2017-05-02 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-05-01 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-09-29 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-09-29 | 다운그레이드 | SunTrust | Buy → Neutral |
모두보기
Intra Cellular Therapies Inc 주식(ITCI)의 최신 뉴스
Trend Tracker for (ITCI) - news.stocktradersdaily.com
Zynext Ventures Invests in Feldan Therapeutics to Drive Innovation in Intracellular Drug Delivery - Yahoo Finance
JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal - TradingView
Johnson & Johnson Reports Q1 2025 Results - BioSpace
Intra-Cellular Therapies’ SWOT analysis: acquisition shifts landscape for psychiatric drug stock - Investing.com Canada
Intra-Cellular Therapies’ SWOT analysis: acquisition shifts landscape for psychiatric drug stock By Investing.com - Investing.com South Africa
Johnson & Johnson - drugdiscoverytrends.com
Johnson & Johnson Expects Lower Earnings Impact From Intra-Cellular Therapies Acquisition - MSN
J&J acquires Intra-Cellular Therapies in multi-billion-dollar deal - ROI-NJ
J&J to complete acquisition of Intra-Cellular Therapies - Medical Buyer
JnJ closes Intra-Cellular Therapies acquisition - Medical Dialogues
JNJ forecasts 2025 profit dilution from Intra-Cellular deal, sets closing date - MSN
Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews - Benzinga
Intra-Cellular Therapies acquired by Johnson & Johnson for $14.6 billion - Investing.com South Africa
Intra-Cellular Therapies Completes Merger with Johnson & Johnson - TipRanks
Johnson & Johnson acquires Intra-Cellular Therapies By Investing.com - Investing.com South Africa
Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended - Benzinga
Johnson & Johnson Acquires Intra-Cellular Therapies - citybiz
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership - BioSpace
Johnson & Johnson Completes Intra-Cellular Therapies Purchase - MarketScreener
JNJ Completes Acquisition Of Intra-Cellular Therapies - Nasdaq
Johnson & Johnson acquires Intra-Cellular Therapies - Investing.com
Johnson & Johnson completes Intra-Cellular Therapies acquisition, sees dilution - TipRanks
Johnson & Johnson (JNJ) Closes Intra-Cellular Therapies, Inc. (ITCI) Acquisition - StreetInsider
Johnson & Johnson Expands Its Horizon With Intra-Cellular Therapies Deal - Finimize
Johnson & Johnson Set To Complete Acquisition Of Intra-Cellular Therapies By April 2, 2025 - Nasdaq
Johnson & Johnson to finalize Intra-Cellular buyout By Investing.com - Investing.com Canada
Johnson & Johnson to finalize Intra-Cellular buyout - Investing.com
Johnson & Johnson Intra-Cellular acquisition to accelerate FY25 sales by 0.8% - TipRanks
Johnson & Johnson (JNJ) Sets April 2nd as Expected Closing Date for Intra-Cellular Acquisition - StreetInsider
Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition - The Joplin Globe
Intra-cellular Therapeutics Surges to 322nd in Trading Volume Ranking with 3.36 Billion Shares Exchanged - AInvest
(ITCI) On The My Stocks Page - news.stocktradersdaily.com
Intra-cellular Therapies Surges to 340th in Daily Rankings with 2.46 Billion Turnover - AInvest
Intra-Cellular Therapies Stock Hits All-Time High of $131.79 By Investing.com - Investing.com South Africa
Intra-Cellular Therapies Shareholders Approve Johnson & Johnson Merger - Investing.com
Intra-Cellular Therapies Shareholders Approve Johnson & Johnson Merger By Investing.com - Investing.com Australia
Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Intra-Cellular Therapies Stock Hits All-Time High of $131.79 - Investing.com
Intra-Cellular Therapies: These Are 5 Critical Challenges Threatening Its Expansion Plans! - Smartkarma
Intra-Cellular Therapies announces proxy statement supplement By Investing.com - Investing.com South Africa
Intra-Cellular Therapies announces proxy statement supplement - Investing.com
Intra-Cellular Therapies stockholder filed lawsuit against co, board in NY Supreme Court - Marketscreener.com
Intra-Cellular Therapies Stock Hits All-Time High of $131.47 By Investing.com - Investing.com UK
Intra-Cellular Therapies (ITCI): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
US Bancorp DE Sells 4,330 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
Scrip M&A Podcast: Looking At M&A Activity As Q1 Nears A Close - Scrip
Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.com - Defense World
Intra-Cellular Therapies Stock Hits All-Time High of $131.37 By Investing.com - Investing.com Australia
Intra-Cellular Therapies Stock Hits All-Time High of $131.37 - Investing.com
Jones Financial Companies Lllp Acquires 2,750 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
Intra Cellular Therapies Inc (ITCI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.16%
1.64%
자본화:
|
볼륨(24시간):